Kura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in three major investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in three major investor conferences in September 2025.
The company will present at the Cantor Global Health Conference on September 4 at 8:35 a.m. ET, the H.C. Wainwright Global Investment Conference on September 8 at 1:00 p.m. ET, and the Morgan Stanley Global Healthcare Conference on September 10 at 1:50 p.m. ET. Live webcasts will be available on Kura's website with archived replays accessible after the events.
Details
News Market Reaction – KURA
On Aug 28, the day this news came out, KURA closed 2.67% above the previous close.
Data tracked by StockTitan Argus for the Aug 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three investor conferences in September.
Cantor Global Health Conference
Thursday, September 4, 2025
8:35 a.m. ET / 5:35 a.m. PT
H.C. Wainwright 27th Annual Global Investment Conference
Monday, September 8, 2025
1:00 p.m. ET / 10:00 a.m. PT
Morgan Stanley 23rd Annual Global Healthcare Conference
Wednesday, September 10, 2025
1:50 p.m. ET / 10:50 a.m. PT
Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following all three events.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.